British American Tobacco p.l.c. · LSE:BATS
British American Tobacco p.l.c — Investor Day (November 2016)
54 slides from British American Tobacco p.l.c's investor day presentation, Nov 17, 2016
Slide 1: "The material in this presentation is provided for the purpose of giving information about
"The material in this presentation is provided for the purpose of giving information about us to investors and is not provided for tobacco product advertising, promotional or marketing purposes. This material does not constitute and should not be construed as constituting an offer to sell, or a soli
Slide 2: Inspiring Products. Driving Change.
INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S
Slide 3: Inspiring Products. Driving Change. Nicandro Durante
INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Nicandro Durante Chief Executive Officer
Slide 4: Our Next Generation Products Journey
OUR NEXT GENERATION PRODUCTS JOURNEY INSPIRING Substantial Share Of P RO D U C T S . £15BN DRIVING NGP Category CHANGE. by 2020
Slide 5: Inspiring Products. Driving Change. Kingsley Wheaton
INSPIRING PRODUCTS. DRIVING CHANGE . L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Kingsley Wheaton Managing Director – Next Generation Products
Slide 6: Agenda
AGENDA 01 AMBITION 02 INSPIRING PRODUCTS. DRIVING CHANGE. 03 R&D & SCIENCE 04 LEADING IN VAPOUR 05 THE NEW TASTE SENSATION 06 CONCLUSIONS
Slide 7: Inspiring Products. Driving Change.
INSPIRING PRODUCTS. DRIVING CHANGE. ____ Substantial share of £15BN NGP Category by 2020
Slide 8: Portfolio
INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns
Slide 9: More Choice, More Innovation, Potentially Less Harm
MORE CHOICE, MORE INNOVATION, POTENTIALLY LESS HARM TOBACCO HEATING PLATFORM HYBRID CLOSED VAPOUR SYSTEMS OPEN VAPOUR SYSTEMS PRODUCTS CONTAINING Tobacco Tobacco & eLiquid eLiquid eLiquid Tobacco sensorials Simplicity Performance Tobacco affinity Simplicity CONSUMER NEEDS Flavour exploration Customi
Slide 10: Creating Inspiring Products. Driving Change.
CREATING INSPIRING PRODUCTS. DRIVING CHANGE. INSPIRING PRODUCTS. DRIVING CHANGE. CLEAR, CONFRONTING OUTSTANDING SIMPLE INSPIRING TOXICANT UNAMBIGUOUS MISINFORMATION SENSORIAL & INTUITIVE PRODUCT REDUCTION CONSUMER & MYTHS EXPERIENCES SYSTEMS DESIGN & USER & CLAIMS INFORMATION HEAD-ON EXPERIENCE INDU
Slide 11: Differentiated Branding: Because Consumers Are Not Homogenous
DIFFERENTIATED BRANDING: BECAUSE CONSUMERS ARE NOT HOMOGENOUS TOBACCO HEATED PLATFORM HYBRID VAPOUR SYSTEMS PRODUCTS HIGHER LOWER TOBACCO TOBACCO AFFINITY AFFINITY DEVICE BRANDING DEVICE BRANDING LUCKY STRIKE ROTHMANS LUCKY STRIKE PALL MALL GLOBAL ROTHMANS PALL MALL DUNHILL DUNHILL DRIVE CONSUMABLE
Slide 12: Branding
INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns
Slide 13: Dr. David O'Reilly, Group Scientific and R&D Director
INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S Dr. David O’Reilly Group Scientific and R&D Director
Slide 14: Harm Reduction and the Model Risk Continuum
HARM REDUCTION AND THE MODEL RISK CONTINUUM TOBACCO LOW TOXICANT LICENSED CONVENTIONAL ELECTRONIC HEATING SMOKELESS MEDICIAL CIGARETTES CIGARETTES PRODUCTS TOBACCO PRODUCTS HIGH EXPOSURE TO TOXICANTS LOW LOW TOXICANT SMOKELESS TOBACCO LICENSED MEDICINAL PRODUCTS TOBACCO HEATING PRODUCTS? CONVENTIONA
Slide 15: Industry-Leading Tools to Substantiate Reduced Risk
WE ARE USING INDUSTRY-LEADING TOOLS TO SEEK TO SUBSTANTIATE REDUCED RISK ACROSS OUR NEXT GENERATION PRODUCTS Potential Potential
Slide 16: A Three-Step Scientific Journey to Substantiate Reduced Risk
A THREE-STEP SCIENTIFIC JOURNEY TO SEEK TO SUBSTANTIATE REDUCED RISK 01 02 03 EMISSIONS EXPOSURE RISK Chemical studies in laboratories using One week human studies demonstrating 6–12 month human studies demonstrating smoking/vaping machines comparing switching to NGPs results in lower changes on swi
Slide 17: Our NGPs Deliver a Different Aerosol to Cigarette Smoke
OUR NGPs DELIVER A DIFFERENT AEROSOL TO CIGARETTE SMOKEa › Cigarettes burn tobacco at around 900˚Cb › glo™ heats tobacco up to a maximum of 240˚Cc › Vype™ heats liquids at around 250˚C aThese qualities do not necessarily mean this product produces less adverse health effects than other tobacco produ
Slide 18: glo and Vype Produce a Different Aerosol Versus a Cigarette
glo™ & Vype™ PRODUCE A DIFFERENT AEROSOL VERSUS A CIGARETTEa,b MACHINE GENERATED AEROSOL CONDENSATE COLLECTED ON FILTER PADS cigarette glo™ Vype™ The glo™ and Vype™ aerosol collected on a glass fibre pad does not contain all the tar related substances of cigarette smoke aMachine puffing conducted un
Slide 19: Next Generation Product Emissions
NEXT GENERATION PRODUCT EMISSIONS COMPARISON OF NGP EMISSIONS AGAINST A SCIENTIFIC REFERENCE CIGARETTEa Cigarette smoke glo™ emissions Vype™ emissions Simpler aerosol composed of fewer constituents aChemical screening of emissions from a scientific reference cigarette (3R4F), glo and vype using a co
Slide 20: Our NGPs Deliver Around 90% Less Toxicants Versus Cigarette Smoke
OUR NGPs DELIVER AROUND 90% LESS TOXICANTS VERSUS CIGARETTE SMOKEa 100% Reference reference 9mg cigarette (3R4F) cigarette Acetaldehyde Acrolein Formaldehyde Carbon monoxide (CO) TOXICANT LEVELS Benzo[a]pyrene 1,3-Butadiene glo vype Benzene N-Nitrosnornicotine (NNN) 4-(Methylnitrosamino)-1- ≥ 90% (3
Slide 21: Emissions Continuum
EMISSIONS CONTINUUMa,b % TOXICANTS REDUCTIONS VS 3R4F on WHO 9 TOXICANT LIST O 100 3R4F Best 1mg/cig ‘Tar’ reference 45% ≥ 90% ≥95% % TOXICANTS REDUCTIONS VS BEST 1MG/CIG ‘TAR’ CIGARETTE on WHO 9 TOXICANT LIST O 100 Best 1 mg/cig ‘Tar’ ≈75% ≥95% aThis graph represents an emissions continuum, further
Slide 22: Relative In Vitro Toxicity
RELATIVE IN VITRO TOXICITYA SUBSTANTIALLY LOWER TOXICITY FOR glo™ (DEVELOPMENT PROTOTYPE) AND Vype™ aComparison of glo (development prototype) and Vype versus a scientific reference cigarette (3R4F). These qualities do not necessarily mean that Glo and Vype products produce less adverse health effec
Slide 23: Risk Assessment Needs Clinical Studies as Dose Response Is Key
RISK ASSESSMENT NEEDS CLINICAL STUDIES AS DOSE RESPONSE IS KEY Model Model v v Dose response model A shows that low emissions/exposure relates to low risk, whereas dose response model B shows that even at low emissions/exposure the risk is high
Slide 24: Systems Science, Clinical Studies and Adverse Outcome Pathways
WE ARE USING SYSTEMS SCIENCE, CLINICAL STUDIES AND ADVERSE OUTCOME PATHWAYS FOR RISK ASSESSMENT e-cig 3R4F Systems Sciencea Adverse Outcome Pathwaysb SHORT AND LONG-TERM CLINICAL STUDIES aExemplar of comparative assessment of Vype and 3R4F using next generation sequencing; bExemplar of one of our AO
Slide 25: Our Plan to Assess Risk Reduction Potential of glo and Vype
OUR PLAN TO ASSESS THE RISK REDUCTION POTENTIAL OF glo™ AND VYPE Q3 Q4 H1 H2 H1 H2 H1 2016 2016 2017 2017 2018 2018 2019 Reduced emissions and performance claims Reduced toxicity in lab models Reduced exposure Reduced risk Wave 2: Systems Science Wave 3: Systems Science Wave 1: Systems Science & AOP
Slide 26: Other benefits of NGPs
» Other a benefits of NGPs
Slide 27: Less Odour and Reduced Impact on Indoor Air Quality
OUR NGPs PRODUCE LESS ODOUR AND REDUCE THE IMPACT ON INDOOR AIR QUALITYa INDOOR AIR QUALITY TESTS a ODOUR ASSESSMENT TEST b 4.0E+05 3.5E+05 3.0E+05 2.5E+05 N/cc 2.0E+05 ________ Cigarette 1.5E+05 ________ Glo 1.0E+05 5.0E+04 0.0E+00 0 0.5 1 1.5 2 2.5 3 3.5 4 Time, h Comparative assessment of the imp
Slide 28: Conclusions
CONCLUSIONS • Our NGPs operate in a different manner to cigarettes producing simpler and cleaner aerosols than smoke • Our NGPs have reduced levels of toxicants compared to cigarettes • Vype™ shows greater reduction of toxicant emissions than THPs • Vype™ and glo™ have the potential to be reduced ri
Slide 29: Vapour
VAPOUR
Slide 30: The Largest Vapour Business in the World Outside the USA
THE LARGEST VAPOUR BUSINESS IN THE WORLD OUTSIDE THE USA 55-60% 34.6% 8.6% 4.8% 2.1% All Market Nielsen Retail Audit*, 6MMA Share Internal estimates, retail channel* Internal estimates, retail channel* Internal estimates, retail channel* share, 6MMA share, 6MMA *Retail excludes specialist vape store
Slide 31: Indexed Volume Performance
INDEXED VOLUME PERFORMANCE 900 800 711* UK 700 695 Germany 600 630 Poland 500 400 300 309 Italy 200 226 Romania** 186 France 100 0 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 *UK Index based on Jan ‘15 sales **iFuse
Slide 32: Vapour – The Largest NGP Category by Value
VAPOUR – THE LARGEST NGP CATEGORY BY VALUE GLOBAL SALES OF VAPOUR (£BN) 8 6 4 2 0 2010 2011 2012 2013 2014 2015 2016 Source: Euromonitor
Slide 33: 56% Are Returners, Quitters or New Users
56% ARE RETURNERS, QUITTERS OR NEW USERS CONSUMERS BY SMOKING CHARACTERISTICS (% OF USERS) Source: Source: Kantar, Kantar, EY EY analysis Seven markets, UK,analysis Germany, Poland, France, Italy, Russia & South Korea
Slide 34: Usage Rates Continue to Grow Consistently
USAGE RATES CONTINUE TO GROW CONSISTENTLY CONSUMERS (BOTH REGULAR AND OCCASIONAL) AS A PERCENTAGE OF ADULTS, 2013-2016 Source: Kantar, EY analysis Seven markets, UK, Germany, Poland, France, Italy, Russia & South Korea
Slide 35: Only 25% of Vapours Use a Tobacco Flavour
ONLY 25% OF VAPOURS USE A TOBACCO FLAVOUR MOST OFTEN USED E-LIQUID FLAVOUR (PERCENTAGE OF USERS) 2015 -2016 Source: Source: Kantar, Kantar, EY EY analysis analysis Seven markets, UK, Germany, Poland, France, Italy, Russia & South Korea
Slide 36: Vapour Converts Substantially More CPTO to Margin
VAPOUR CONVERTS SUBSTANTIALLY MORE CPTO TO MARGIN € Per unit WAP FMC Vype vPro € Per unit WAP FMC Vype Liquid GM as % of RRP 12.9% 27.4% GM as % of RRP 6.2% 28.0% Absolute €0.58 €1.90 Absolute €0.16 €1.19 % OF CPTO % OF CPTO 100% 100% 90% 90% 80% 80% Tax Tax 70% 70% 60% 60% Trade Trade 50% margin 50
Slide 37: Introducing Vype Pebble
INTRODUCING VYPE PEBBLE
Slide 38: Small and Mighty
SMALL AND MIGHTY BLUE’S THE DADDY THE NEXT SMALL THING SMALL DARK & HANDSOME AWESOME AND SOME POCKET ROCKET
Slide 39: Vype Pebble Features & Benefits
VYPE PEBBLE FEATURES & BENEFITS CARTRIDGE GOLDEN VELVET TINGLING TOBACCO TOBACCO MINT Palm fit size, ergonomic, poke- DESIGN nomics, easy to use, stylish, range of colours All day charge, elegant design POWERFUL & INTUITIVE WILD FRESH SMOOTH system BERRIES APPLE VANILLA Rich satisfying vapour,
Slide 40: Full bleed hero retail image here
Full bleed hero retail image here
Slide 41: One Touch to Enjoy Next Generation Heating Tobacco glo
ONE TOUCH TO ENJOY NEXT GENERATION HEATING TOBACCO “gloTM”
Slide 42: Multiple Benefits to the glo System Proposition
MULTIPLE BENEFITS TO THE GLO SYSTEM PROPOSITION
Slide 43: Multiple Benefits to the glo System Proposition
MULTIPLE BENEFITS TO THE GLO SYSTEM PROPOSITION
Slide 44: Three Exceptional Flavours, Researched Extensively
THREE EXCEPTIONAL FLAVOURS, RESEARCHED EXTENSIVELY BRIGHT TOBACCO FRESH MIX INTENSELY FRESH Complex mix Well balanced Exhilarating of mint and & mellow with burst of cooling, velvety notes bright, roasted balanced with balanced with malty notes fresh mint refreshing menthol
Slide 45: World First Coming to Sendai 12.12.16
“WORLD FIRST COMING TO SENDAI 12.12.16”
Slide 46: Slide 46
Slide 47: We Believe Less Is More
2°2| NGP gle WE BELIEVE| a LESS IS MORE.
Slide 48: Device Customisation Lends a World of Opportunity
DEVICE CUSTOMISATION LENDS A WORLD OF OPPORTUNITY DEVICE COLOUR VARIANTS SLEEVES PR INFLUENCERS LIMITED EDITION COLOUR VARIATION
Slide 49: Our First Flagship Store in Sendai
OUR FIRST FLAGSHIP STORE IN SENDAI
Slide 50: Supply Chain
INSPIRING PRODUCTS. DRIVING CHANGE. Portfolio Branding R&D & Science Regulatory Strategy Supply Chain Investment & Returns
Slide 51: Supply Chain Manufacturing Integration
SUPPLY CHAIN MANUFACTURING INTEGRATION: CURRENTLY RUSSIA & SOUTH KOREA BUILDING SUBSTANTIAL CAPACITY IN 2017 & 2018 2x 2018 vs 2017
Slide 52: Japan: glo Is More Than 2x Margin vs FMC
JAPAN: vs FMC CHECK DATA £ Per unit FMC gloTM is more than 2x margin GM as % of RRP 14.1% 36.2% Absolute £0.42 £1.08 generating versus cigarettes % OF CPTO 100% 90% Tax Longer term, COGS profile 80% 70% will reduce as volumes scale Trade 60% margin 50% COGS 40% 30% RRP Fiscal policy based on model 2
Slide 53: Delivering Today. Investing in Tomorrow.
DELIVERING TODAY. INVESTING IN TOMORROW. Consumer Centric. More innovation, Inspiring Products. more choice, $1bn investment Driving Change less harm so far in NGP Vapour will be the Tobacco Heating Substantial share of largest category will have pockets of strength and £15BN and has can be margin N
Slide 54: Inspiring Products. Driving Change.
INSPIRING PRODUCTS. DRIVING CHANGE. L E A D I N G I N N E X T G E N E R AT I O N P R O D U C T S
British American Tobacco — Investor Day (November 2016) on 6ix